EIKN (NASDAQ:EIKN) Coverage Initiated by Analysts at Bank of America

Analysts at Bank of America assumed coverage on shares of EIKN (NASDAQ:EIKN) in a report released on Monday,Benzinga reports. The brokerage set a “buy” rating and a $34.00 price target on the stock. Bank of America‘s price objective would suggest a potential upside of 146.73% from the stock’s current price.

Other analysts have also issued research reports about the company. Wall Street Zen raised EIKN to a “hold” rating in a research note on Monday, February 16th. Wedbush initiated coverage on shares of EIKN in a report on Thursday. They issued an “underperform” rating and a $7.00 target price on the stock. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.75.

EIKN Price Performance

NASDAQ EIKN opened at $13.78 on Monday. EIKN has a 1-year low of $13.28 and a 1-year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.